GERON CORP
GERON CORP (GERN): 3 pipeline candidates · 2 upcoming catalysts · ~9 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
9.4 months
D/E 1.33
Lead: Approved
3 candidates
2 upcoming, next in ~743d
0 buys · 1 sell (180d)
A transparent, data-derived signal for GERON CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$789.1M
Cash
$68.9M
Quarterly Burn
$62.9M
Runway
9.4 mo
Revenue
$51.8M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| best available therapy | Phase 3 |
| imetelstat | Phase 2 |
| rytelo | Approved |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
252
Total value held
$676.7M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 63,771,366 | $95.0M |
| vanguard capital management llc | 53,338,058 | $79.5M |
| blackrock, inc. | 47,319,779 | $70.5M |
| deep track capital, lp | 31,720,278 | $47.3M |
| state street corp | 30,497,183 | $45.4M |
| citadel advisors llc | 22,110,669 | $32.9M |
| clearbridge investments, llc | 19,620,320 | $29.2M |
| vivo capital, llc | 17,343,594 | $25.8M |
| geode capital management, llc | 13,670,785 | $20.4M |
| morgan stanley | 12,665,119 | $18.9M |
Showing top 10 of 252 institutional holders of GERON CORP. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in GERON CORP's pipeline?
GERON CORP (GERN) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is GERON CORP's lead drug candidate?
GERON CORP's most advanced tracked candidate is best available therapy (Phase 3) for Myelofibrosis.
What is GERON CORP's next catalyst?
GERON CORP's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therap" — expected June 30, 2028.
What is GERON CORP's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, GERON CORP has approximately 9.4 months of cash runway.
What is GERON CORP's market capitalization?
GERON CORP's market capitalization is approximately $789.1M.
Get the full picture on GERON CORP
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.